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Abstract
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO)
compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either
with ATO+ all-trans retinoic acid (ATO/ATRA; n= 26), CTX/ATRA+ATO during consolidation (CTX/ATRA/ATO;
n= 148), or with CTX/ATRA (n= 259). Median follow-up for overall survival (OS) was 4.8 years. Complete remissions
(CR) were achieved in 92% with ATO/ATRA and 82% with CTX/ATRA; induction death rates were 8% and 18%,
respectively. For analysis of postremission outcomes we combined the ATO/ATRA and CTX/ATRA/ATO groups (ATO/
ATRA ± CTX). Cumulative incidence of relapse (CIR) was significantly lower after ATO/ATRA ± CTX compared with
CTX/ATRA (P < 0.001). The same held true when restricting the analysis according to the treatment period after the year
2000. OS of patients in CR1 was not different between ATO/ATRA ± CTX compared with CTX/ATRA (P= 0.20). High
(>10 × 109/l) white blood cell (WBC) counts at diagnosis were associated with higher CIR (P < 0.001) compared with lower
WBC in the CTX/ATRA group, but not in the ATO/ATRA ± CTX group (P= 0.48). ATO, when added to ATRA or CTX/
ATRA is feasible and effective in elderly patients for remission induction and consolidation, particularly in patients with
high WBC at diagnosis.
Introduction
Upfront arsenic trioxide (ATO) and all-trans retinoic acid
(ATRA) combination has been proven to be highly effective
in acute promyelocytic leukemia (APL) and has become
standard therapy in younger adult, nonhigh-risk patients
[1, 2]. Within the pre-ATO era, high white blood cell
(WBC) counts were identified as a risk factor for relapse [3–
6]. After initial induction treatment with ATRA and idar-
ubicin (AIDA), subsequent risk-adapted consolidation
therapy has shown to partly equalize the risk of relapse
between APL-risk groups [5, 7].
To date, reports on outcome of older APL patients (≥70
years) with ATO/ATRA are scarce [8, 9]. Although the
approval of ATO in the USA and Europe was based on the
randomized APL0406 study in patients 18–70 years of age
[1, 2] no upper age limit for the treatment with ATO/ATRA
was included in both labels. Thus, clinical data on patients
above the age of 70 years treated with different regimens
will help clinicians to identify best treatment options for
their older APL patients.
In addition, a high mortality before start and during the
first day of treatment is still a major issue in APL, particu-
larly in older patients according to the Swedish adult acute
leukemia registry [10]. Early death rates after ATRA±
anthracycline-based induction therapy were as high as 60%
in patients above the age of 80 years and still 18.8% in
patients aged 50–59 years [10]. Furthermore, despite dose
reduction of chemotherapy (CTX) in older patients [11–13]
non-relapse mortality during postremission therapy remained
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high, with 10–18.6% dying mainly due to infections,
whereas it was much lower (6.9%) after therapy with ATO
[8]. In contrast to CTX/ATRA, only single cases with a
secondary malignancy are reported after ATO treatment [8].
The objectives of our study were to evaluate character-
istics and outcome of older (≥70 years) APL patients treated
with different treatment strategies in a large, international
cooperative cohort of patients.
Patients and methods
Patients and treatment
Data on 475 patients aged ≥70 years, reported either to the
multicenter, multinational registries German Intergroup
Napoleon registry (n= 28), Spanish PETHEMA (Programa
Español de Tratamientos en Hematología, n= 211), or
French APL Group (n= 228) or to the local data base at the
Johns Hopkins University of Maryland, USA (n= 8), were
collected in a large international collaboration. All patients
were treated between 1990 and 2018. Patients who were
treated less intensively with single-agent ATRA or in
combination with low-dose cytarabine or comparable CTX
(n= 38) or patients with lacking data on response and
survival (n= 4) were excluded from analysis. The final
study cohort consisted of n= 433 patients. Diagnosis of
APL was based on genetic analysis as well as on
French–American–British Cooperative Group criteria [14],
and, after 2003, on revised International Working Group
criteria [15]. Chromosome banding was performed using
standard techniques, and karyotypes were described
according to the International System for Human Cytoge-
netic Nomenclature [16]. The diagnosis was confirmed by
either reverse-transcriptase polymerase chain reaction (RT-
qPCR) or fluorescence in situ hybridization detection by
standard methods. FLT3 mutation screening for internal
tandem duplications (ITD) and point mutations within the
tyrosine kinase domain (TKD) was carried out as previously
described [17, 18]. Data collection and analysis were
approved by the local Institutional Review Boards.
Treatment
Two-hundred and fifty-nine patients (60%) were treated
with ATRA and an anthracycline (daunorubicin or idar-
ubicin) as induction and different CTX in combination with
ATRA as consolidation therapy according to treatment
protocols active in various institutions and cooperative
groups (Supplementary Table 1). These protocols included
the PETHEMA LPA96 [19] (n= 23), LPA99 [20] (n= 45),
LPA2005 [21] (n= 76), and LPA2012 (ClinicalTrials.gov
Identifier: NCT02020161; n= 31), the French APL93 [7]
(n= 34) and APL2000 [22] (n= 41) trials, as well as
standard AIDA-based CTX [23] (n= 9). Twenty-six (6%)
patients were treated with ATO/ATRA [1] (including one
dose of idarubicin, n= 1 or daunorubicin for ATRA-syn-
drome, n= 1; and 5 days of decitabine, n= 1). In addition,
148 (34%) patients were treated with CTX/ATRA+ATO
according to the French APL2006 trial [24] (n= 144), or
according to Gore et al. [25] (n= 4). Response and treat-
ment failure were assessed according to Cheson et al. [15].
Statistical analyses
Overall survival (OS) was defined as recommended [15].
Induction death was defined as death occurring before
complete remissions (CR) evaluation, occurring at the latest
within 43 days after treatment initiation in our cohort.
Comparisons of patient characteristics were performed
with the Kruskal–Wallis rank sum test for continuous
variables and Fisher’s exact test for categorical variables,
respectively. The median follow-up time was computed
using the reverse Kaplan–Meier estimate [26]. The
Kaplan–Meier method was used to estimate the distribution
of OS [27]. Confidence interval (CI) estimation for survival
curves was based on the cumulative hazard function using
Greenwood’s formula for variance estimation. Logrank tests
were employed to compare survival curves between groups.
For cumulative incidence of relapse (CIR) and death (CID),
equality of cumulative incidences between the treatment
groups was evaluated using the Gray’s test [28]. A cause-
specific Cox proportional hazards regression model was
used to identify prognostic variables for relapse [29]. The
following variables were included in the Cox model: age at
diagnosis, gender, APL treatment (ATO/ATRA ± CTX vs.
CTX/ATRA), and WBC count (dichotomized, ≤10 × 109/l
vs. >10 × 109/l). All statistical analyses were performed
with the statistical software environment R, version 3.3.1,
using the R packages, and survival, version 2.39-5 [30].
Results
In total, 433 older APL patients, diagnosed between 1990
and 2015 from four study groups/institutions in the USA
and Europe, were included. Median age was 73.4 years
(range, 70–89 years).
Risk categorization based on WBC count at diagnosis
was available in 429 (99%) of the 433 patients and was
low-/intermediate-risk (WBC ≤ 10 × 109/l) in 339 (79%) and
high-risk (WBC > 10 × 109/l) in 90 (21%) patients.
Information on cytogenetics was available in 381 (88%)
patients. In 26 (7%) of the 381 patients t(15;17) could only
be detected by FISH and/or RT-qPCR, whereas cytoge-
netics showed a normal karyotype. In 238 (67%) of the
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remaining 355 patients, the balanced t(15;17) translocation
was the sole abnormality, whereas in 117 (33%) patients,
the translocation was accompanied by additional cytoge-
netic abnormalities, most frequently trisomy 8 (n= 7; 6%)
or t(15;17) within a complex karyotype (≥2 cytogenetic
abnormalities in addition to t(15;17); n= 12; 10%).
Regarding FLT3-ITD and TKD mutations, information
was available in only 56 (13%) of the 433 patients. Of
those, eight (14%) patients had FLT3-ITD and two (4%)
had a FLT3-TKD mutation. Patients with FLT3-ITD
mutations had significantly higher WBC at diagnosis as
compared with FLT3 wild type patients (P < 0.001).
Information on the PML-RARA transcript isoform
(breakpoint cluster region (BCR)) was available in 292
patients; 125 (43%) had the short isoform (BCR3). Baseline
characteristics according to the frontline strategy are shown
in Table 1.
Median age was in trend higher in the ATO/ATRA group
as compared with the CTX/ATRA and CTX/ATRA/ATO
groups. Median WBC, percentage of peripheral blood and
bone marrow blasts as well as risk categorization were
significantly lower in the ATO/ATRA ± CTX group as
compared with the CTX/ATRA group.
Response to induction therapy
Overall, 356 patients achieved a CR (82%), two patients
had refractory disease (0.5%) and 75 patients died during
induction therapy (17%). The rate of death during induction
therapy was lower in patients receiving ATO/ATRA (n= 2/
26; 8%) as compared with those receiving CTX/ATRA
(n= 73/407; 18%) as induction therapy (P= 0.28). The rate
of deaths during induction therapy decreased over time from
28% (17 of 60 patients) in 1990–1999, to 15% (29 of 188
patients) in 2000–2009 and 16% (29 of 185 patients) in
2010–2018 (P= 0.07). Main causes of deaths were bleed-
ing/hemorrhage (n= 16), infections (n= 17), differentia-
tion syndrome (n= 9), multi-organ failure (n= 3), as well
as other causes (not further specified; n= 30).
CRs were achieved after induction therapy in 82% with
CTX/ATRA (n= 332/407) and in 92% with ATO/ATRA
(n= 24/26; Table 2; P= 0.29). In a logistic regression
model on response to induction therapy WBC count above
10 × 109/l (P < 0.001) and age above 75 years (P= 0.04)
were unfavorable factors, whereas treatment with ATO/
ATRA was a beneficial, but not a significant factor (P=
0.34; Table 3). APL was refractory after CTX/ATRA
treatment in two patients, who died after 51 and 477 days
from diagnosis, respectively. None of the patients in the
ATO/ATRA group was refractory.
Of twelve patients with a complex karyotype, eight were
treated with AIDA-based regimen, whereas four patients
received ATO/ATRA. Two patients treated with AIDA died
after induction therapy and two patients relapsed, whereas
no induction death or relapse occurred after ATO/ATRA
treatment.
Survival analysis
Median follow-up for survival was 4.8 years (95% CI,
4.3–5.6 years). Overall, the estimated 5-year OS rate was
66% (95% CI, 61–71%). As we were interested in the effect
of ATO on CIR and CID, as well as survival of CR patients
we combined ATO/ATRA and CTX/ATRA+ATO in one
Table 1 Comparison of presenting clinical and laboratory findings











Median 73.4 73.2 76 0.07
Range 70–88.7 70–89 71–87
Gender, no. (%)
Male 123 (47) 80 (54) 18 (69) 0.07
Female 136 (53) 68 (46) 8 (31)
WBC, ×109/l
Median 2.1 1.3 0.8 <0.001
Range 0.1–764 0.2–136 0.2–3.6
Missing 4 0 0
Hemoglobin, g/dl
Median 9.2 9.7 9.2 0.20
Range 4.0–15.2 4.6–14.3 6.0–14.0
Missing 14 2 17
Platelet count, ×109/l
Median 34 41 43 0.08
Range 3–213 4–261 11–195
Missing 8 3 2
Percentage of PB blastsa
Median 61 6 1 <0.001
Range 0–100 0–99 0–67
Missing 53 15 7
Percentage of BM blastsa
Median 80 74 50 0.005
Range 13–100 12–98 3–90
Missing 42 0 11
High-riskb 72 (28) 18 (12) 0 <0.001
Missing 4 0 0
Percentages may not add to 100 because of rounding.
ATO arsenic trioxide, ATRA all-trans retinoic acid, BM bone marrow,
CTX chemotherapy, PB peripheral blood, WBC white blood cell
counts.
aBlast cells included malignant promyelocytes.
bHigh risk: WBC > 10 × 109/l.
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group (ATO/ATRA ± CTX). Treatment with ATO/ATRA±
CTX was associated with significantly reduced CIR after 5
years (4% vs. 18%; P < 0.001; Fig. 1a) with no significant
differences in CID (12% and 13%; P= 0.73; Fig. 1b) and
OS rates of CR patients (84% (95% CI, 78–91) vs. 77%
(95% CI, 71–84%); P= 0.20; Fig. 2) as compared with
CTX/ATRA. When restricting the analysis according to the
treatment period after the year 2000, ATO/ATRA ± CTX
was still associated with significantly lower CIR (P= 0.02)
as compared with CTX/ATRA. Of note, higher WBC counts
at diagnosis (>10 × 109/l) were associated with an increased
CIR in CTX/ATRA (P < 0.001; Fig. 3a), but not in ATO/
ATRA± CTX (P= 0.48; Fig. 3b).
Overall, five patients relapsed after ATO/ATRA ± CTX
(median time from CR to relapse, 18.2 months) as com-
pared with 33 after CTX/ATRA (median time from CR to
relapse, 5 months). Of those, risk categorization was high in
one patient of the ATO/ATRA ± CTX group as compared
with 22 patients of the CTX/ATRA group.
Only two patients experienced besides a hematological a
CNS relapse. Both relapses occurred after AIDA-based
therapy. Radiotherapy was applied in one patient, whereas
the other patient received no treatment. Both patients died
shortly after relapse (13 days and 98 days).
Of the CTX/ATRA group eight patients received ATO
and additionally five patients ATO/ATRA as salvage ther-
apy. Overall, 12 of the 13 relapsed patients of the CTX/
ATRA group achieved a second remission, whereas one
patient died during salvage therapy. Multivariate analysis
showed that higher WBC count (>10 × 109/l; hazard ratio
(HR), 7.90; P < 0.001) had an adverse impact on relapse,
whereas therapy with ATO/ATRA ± CTX (HR, 0.23; P=
0.003) was beneficial (Table 4).
Fifty-five patients died in remission (CTX/ATRA, n=
37; ATO/ATRA ± CTX, n= 18), mainly due to infections
(n= 12; CTX/ATRA, n= 7 and ATO/ATRA+CTX, n=
5), bleeding/hemorrhage (n= 9; CTX/ATRA, n= 2 and
ATO/ATRA+CTX, n= 7), cardiac arrest+ aneurysm
rupture in the brain (ATO/ATRA+ CTX, n= 1), ence-
phalitis/cerebellitis (ATO/ATRA+ CTX, n= 2), prostate
cancer (ATO/ATRA+ CTX, n= 1), and unknown causes
(n= 30; CTX/ATRA, n= 28 and ATO/ATRA+ CTX,
n= 2).
Among patients achieving CR after intensive therapy, the
median follow-up time was 3.4 years for ATO/ATRA ±
CTX and 7.2 years for CTX/ATRA. Data on the
Table 3 Logistic regression model on response to induction therapy.
Regression model on response
to induction therapy
OR P value
Age above 75 years 0.55 0.030
WBC (>10 × 109/l) 0.26 <0.001
ATO/ATRA 2.21 0.30
Male gender 0.72 0.22
ATO arsenic trioxide, ATRA all-trans retinoic acid, CTX chemotherapy,
OR odds ratio, WBC white blood cell count.






CR 82 (332) 92 (24)
RD 0.5 (2) –
ID 18 (73) 8 (2)
Missing data, n= 3 (CTX/ATRA). Percentages may not add to 100
because of rounding.
ATO arsenic trioxide, ATRA all-trans retinoic acid, CR complete



































































Fig. 1 Cumulative incidence of relapse (CIR, a) and cumulative incidence of death (CID, b) according to treatment strategy. ATO arsenic trioxide,
ATRA all-trans retinoic acid, CTX chemotherapy, n number.
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development of secondary neoplasms were available in 163
patients. Of those, 11 (7%) patients developed a secondary
neoplasm (gastro-intestinal cancer, n= 4; lung cancer, n=
3; neuroendocrine carcinoma, n= 1; and secondary acute
myeloid leukemia, n= 3) after a median of 61.5 months
(range, 5.5–85 months) from the time point of CR. All of
them had been treated with CTX/ATRA. In a competing
risk analysis among patients in CR after intensive therapy,
the rate of secondary malignancies was significantly lower
after ATO/ATRA ± CTX as compared with CTX/ATRA
(P= 0.02).
Discussion
Our retrospective analysis of a large cohort of 433 older
APL patients, spanning a time period of almost 28 years,
shows a higher response rate after treatment with ATO/
ATRA as compared with CTX/ATRA, primarily due to a
lower rate of induction deaths, which is in line with pub-
lished data in younger APL patients [1, 9]. The rate of
induction deaths decreased from 28% between 1990 and
1999 to 15% and 16% of the following decades, which may
be attributable to improved supportive care and awareness
of APL as a medical emergency. This finding suggests that
the clear guidance in international recommendations about
early supportive care has had an effect in recent years [31].
Thus, an effective strategy to overcome induction mortality
is due to standardized guidelines along with consultative
support and sharing of expertise [32]. Main causes of
induction death after CTX/ATRA included bleeding/
hemorrhage and infections, which is in line with previously
published data [10, 33, 34]. However, 30 patients experi-
enced induction death due to other causes, which might
simply be related to the fact, that older patients might have
more frequent and severe comorbidities and thus lower
capacity to tolerate CTX [10]. The main limitation of CTX/
ATRA treatment is the high rate of induction death, whereas
treatment with ATO/ATRA seems to be safer and being
associated with a low-induction death rate. Thus, treating
patients with ATO/ATRA during induction seems to be
rational rather than in consolidation, when the greatest risk
has passed [35]. However, in our cohort the number of
patients treated with ATO/ATRA during induction was very
low and induction mortality was high after CTX/ATRA,
particularly in the earlier treatment period before 1999.
Therefore, a comparison of OS between the CTX/ATRA
and ATO/ATRA groups is hampered. Thus, we focused in
time-to-event analyses on patients in first CR.
As a potential selection bias, none of the patients treated
with ATO/ATRA in induction therapy had high risk (WBC





















Fig. 2 Overall survival. Overall survival of patients achieving a
































WBC ≤ 10 109/l, n=146


































WBC ≤ 10 109/l, n=146
WBC > 10 x 109/l, n=16 
P=0.48
Fig. 3 Cumulative incidence of relapse according to risk category
and treatment. a Cumulative incidence of relapse according to risk
category (white blood cell count ≤10 × 109/l vs. >10 × 109/l) in patients
treated with all-trans retinoic acid and chemotherapy. b Cumulative
incidence of relapse according to risk category (white blood cell
count ≤10 × 109/l vs. >10 × 109/l) in patients treated with arsenic
trioxide-based regimens.
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CTX/ATRA group, which is a known risk factor for
bleeding diathesis [3]. In addition, as a further potentially
selection bias, percentage of peripheral blood and bone
marrow blasts were also unequally distributed between the
CTX/ATRA and ATO-based groups.
Regarding postremission outcome, results of the ran-
domized North American Leukemia Intergroup Study
C9710 on 481 APL patients (age range, 15–79 years
including 77 patients above the age of 60 years) evalu-
ating ATO in first-line therapy during consolidation
demonstrated that ATO further reduced the risk of relapse
and improved survival as compared with consolidation
with daunorubicin/cytarabine [35]. In contrast, a subgroup
analysis of the randomized phase-III AML17 trial of the
UK National Cancer Research Institute Acute Myeloid
Leukaemia Working Group on 49 older (age range,
≥60–77 years) patients showed no significant difference of
the 4-year OS rate after treatment with ATO/ATRA (74%;
n= 25) as compared with the AIDA-based regimen (80%;
n= 24) [9]. However, this was in contrast to the total
study cohort with significantly better event-free and
relapse-free survival after ATO/ATRA as compared with
the AIDA-based regimen. In our cohort postremission
outcomes were comparable after CTX/ATRA and ATO-
based treatment in patients with low-/intermediate-risk,
which is in contrast to previously published data in
younger adults [1, 2]. Contrary to the data of the AML17
trial [9], the ATO-based treatment resulted in significant
lower CIR in patients with high-risk.
There was no difference between CTX/ATRA and ATO-
based regimens with regard to deaths in remission with
relatively high rates of 12% and 13%, which is probably
due to the advanced age of the cohort. Besides bleeding
infections were the most frequent cause of death, particu-
larly after CTX/ATRA treatment, arguing for a CTX-free
approach. Other causes were most probably related to the
natural death rate.
In addition, there was a significant difference in the
occurrence of secondary malignancies, since none of the
patients developed a secondary therapy-related myeloid
neoplasm or solid tumor after ATO-based regimens as
compared with 11 (7%) patients after CTX/ATRA, includ-
ing four patients, who developed a secondary malignancy
within 2.5 years after achievement of CR. Although the
median follow-up time was shorter after ATO-based regi-
mens as compared with CTX/ATRA, the reported latency
period between APL diagnosis and the development of a
secondary malignancy of 6.6 months strongly argues for a
true lower incidence after ATO/ATRA ± CTX [36]. The
low-relapse rate after ATO-based therapy in our cohort is in
line with others [8, 35]. Moreover, 12 relapsed patients of
the CTX/ATRA group were successfully salvaged with
ATO-based therapy, confirming the tolerability of this
treatment option in elderly patients. In contrast to the pub-
lication of Powell et al. [35] presenting a subgroup analysis
in older patients, treatment with ATO/ATRA was not
superior to the standard CTX/ATRA-approach in the low-/
intermediate-risk in our cohort. However, a clear and sig-
nificant benefit was seen in the high-risk group. Thus, our
data suggest that ATO-based regimens are effective in older
patients independent of risk classification.
Regarding biological characteristics, additional cyto-
genetic abnormalities were present in 25% of the patients,
most frequently trisomy 8, which is in line with published
data [37, 38]. In addition, t(15;17) could also be found
within a complex karyotype, suggesting that older age
might lead to higher chromosomal instability and thus
higher rate of abnormalities, as has been described [39].
Although data were limited to a low number of patients,
FLT3-ITD mutations seem to be less frequent in older
(14%) as compared with all APL patients (31%) [35]. As
expected, FLT3-ITD mutated patients had significantly
higher WBC count at diagnosis as compared with FLT3
wild type patients [37, 40–43]. To date, there are still
conflicting data regarding the impact of additional chro-
mosomal or genetic abnormalities on outcome in APL
patients [37, 40–49]. In our large cohort, the presence of
additional cytogenetic abnormalities had no impact on OS
(P= 0.99), whereas FLT3-ITD was associated with an
adverse impact on OS (P < 0.001). The latter issue,
however, should be interpreted with precaution due to the
low availability of FLT3 mutational status in our cohort.
Regarding the distribution of risk category according to
WBC count at diagnosis, published data are again con-
tradictory [49, 50]. Sanz et al. [49] reported that older
patients seem to be more likely to present with non-high-
risk APL as compared with their younger counterparts
(37% vs. 18%), which in part may account for the low
relapse rate observed in their publication. In contrast,
Lengfelder et al. reported on 31% (n= 28/91) of older
patients with high-risk APL [50]. In our cohort, the pro-
portion of high-risk patients in the CTX/ATRA group was
comparable with the latter publication [50], whereas it was
Table 4 Cause-specific Cox model on relapse risk.
Cause-specific Cox model on
relapse risk
HR P value
Age above 75 years 1.07 0.86
WBC (>10 × 109/l) 7.90 <0.001
ATO/ATRA ± CTX 0.23 0.003
Male gender 0.99 0.99
ATO arsenic trioxide, ATRA all-trans retinoic acid, CTX chemotherapy,
HR hazard ratio, OR odds ratio, WBC white blood cell count.
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lower in the ATO/ATRA/ ± CTX group due to study
inclusion criteria [24] as well as reservation to use ATO-
based therapy in high-risk patients. As expected, higher
WBC count above 10 × 109/l was an unfavorable factor for
response to induction therapy as well as CIR and CID. Of
note, no difference in outcome was observed in high-risk
patients after treatment with ATO/ATRA ± CTX, whereas
this was not the case in patients after treatment with CTX/
ATRA, suggesting that the ATO-based regimen is also
highly active within the high-risk group.
In conclusion, ATO, when added to ATRA or CTX/
ATRA, is a feasible and efficacious treatment and leads to
good outcomes in the primary management of older APL
patients. Thus, it seems to be prudent to expand this
approach to older APL patients.
Author contributions SK, PM, and RFS were responsible for the
concept of this paper, contributed to the literature search data collec-
tion, analyzed and interpreted data, and wrote the paper. UP and LA
contributed patients, interpreted data and critically revised the paper.
RR, DMC, GG, XT, MS, AGB, AG, AP, CG, ER, MT, NV, JS, OS,
EL, MJL, PF, and MAS contributed patients and critically revised the
paper. All authors reviewed and approved the final paper.
Funding Open Access funding enabled and organized by Projekt
DEAL.
Compliance with ethical standards
Conflict of interest SK was supported by the Olympia-Morata fel-
lowship program from the Medical Faculty of the Heidelberg Uni-
versity. MJL is supported by a grant from the NCI (NCI Leukemia
SPORE P50 CA100632). UP has received research support from
TEVA. All other authors declare no competing conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and
arsenic trioxide for acute promyelocytic leukemia. N Engl J Med.
2013;369:111–21.
2. Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes
with retinoic acid and arsenic trioxide compared with retinoic acid
and chemotherapy in non-high-risk acute promyelocytic leukemia:
final results of the randomized Italian-German APL0406 trial. J
Clin Oncol. 2016;35:605–12.
3. Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic
leukemia: strategies to define high-risk patients. Ann Hematol.
2016;95:673–80.
4. Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse
risk and role of nonanthracycline drugs for consolidation in
patients with acute promyelocytic leukemia: a joint study of the
PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:
1247–53.
5. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of
acute promyelocytic leukemia with alltrans-retinoic acid and
anthracycline monochemotherapy: a multicenter study by the
PETHEMA group. Blood. 2004;103:1237–43.
6. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison
of all transretinoic acid (ATRA) followed by chemotherapy and
ATRA plus chemotherapy and the role of maintenance therapy in
newly diagnosed acute promyelocytic leukemia. The European
APL Group. Blood. 1999;94:1192–200.
7. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of
acute promyelocytic leukemia with AIDA induction followed by
risk-adapted consolidation for adults younger than 61 years:
results of the AIDA-2000 trial of the GIMEMA Group. Blood.
2010;116:3171–9.
8. Zhang Y, Zhang Z, Li J, et al. Long-term efficacy and safety of
arsenic trioxide for first-line treatment of elderly patients with
newly diagnosed acute promyelocytic leukemia. Cancer.
2013;119:115–25.
9. Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-
trans retinoic acid treatment for acute promyelocytic leukaemia in
all risk groups (AML17): results of a randomised, controlled,
phase 3 trial. Lancet Oncol. 2015;16:1295–305.
10. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early
death rate in acute promyelocytic leukemia: a population-based
report from the Swedish Adult Acute Leukemia Registry. Leu-
kemia. 2011;25:1128–34.
11. Ades L, Chevret S, De Botton S, et al. Outcome of acute pro-
myelocytic leukemia treated with all-trans retinoic acid and che-
motherapy in elderly patients: the European group experience.
Leukemia. 2005;19:230–3.
12. Mandelli F, Latagliata R, Fazi P, Rodeghiero F, Leoni F, et al.
Treatment of elderly patients (> or =60 years) with newly diag-
nosed acute promyelocytic leukemia. Results of the Italian mul-
ticenter group GIMEMA with ATRA and idarubicin (AIDA)
protocols. Leukemia. 2003;17:1085–90.
13. Disperati P, Minden MD, Gupta V, et al. Acute promyelocytic leu-
kemia in patients aged 70 years and over—a single center experience
of unselected patients. Leuk Lymphoma. 2007;48:1654–8.
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised
criteria for the classification of acute myeloid leukemia. A report
of the French–American–British Cooperative Group. Ann Intern
Med. 1985;103:620–5.
15. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recom-
mendations of the International Working Group for diagnosis,
standardization of response criteria, treatment outcomes, and
reporting standards for therapeutic trials in acute myeloid leuke-
mia. J Clin Oncol. 2003;21:4642–9.
16. Mitelman F. ISCN: an international system for human cytogenetic
nomenclature. Basel: S. Karger; 1995.
17. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of
the FLT3 gene is preferentially seen in acute myeloid leukemia
and myelodysplastic syndrome among various hematological
malignancies. A study on a large series of patients and cell lines.
Leukemia. 1997;11:1605–9.
18. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating
mutations in 979 patients with acute myelogenous leukemia:
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an. . . 2339
association with FAB subtypes and identification of subgroups
with poor prognosis. Blood. 2002;99:4326–35.
19. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol
with anthracycline-based consolidation results in high antileu-
kemic efficacy and reduced toxicity in newly diagnosed PML/
RARalphapositive acute promyelocytic leukemia. PETHEMA
group. Blood. 1999;94:3015–21.
20. Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment
of acute promyelocytic leukemia with all-trans retinoic acid and
anthracycline monochemotherapy: long-term outcome of the LPA
99 multicenter study by the PETHEMA Group. Blood.
2008;112:3130–4.
21. Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment
of acute promyelocytic leukemia based on all-trans retinoic acid
and anthracycline with addition of cytarabine in consolidation
therapy for high risk patients: further improvements in treatment
outcome. Blood. 2010;115:5137–46.
22. Adès L, Chevret S, Raffoux E, et al. Is cytarabine useful in the
treatment of acute promyelocytic leukemia? Results of a rando-
mized trial from the European Acute Promyelocytic Leukemia
Group. J Clin Oncol. 2006;24:5703–10.
23. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in
PML/RAR alpha-positive acute promyelocytic leukemia by
combined all-trans retinoic acid and idarubicin (AIDA) therapy.
Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and
Associazione Italiana di Ematologia ed Oncologia Pediatrica
Cooperative Groups. Blood. 1997;90:1014–21.
24. Rahmé R, Ades L, Thomas X, et al. Reducing mortality in newly
diagnosed standard-risk acute promyelocytic leukemia in elderly
patients treated with arsenic trioxide requires major reduction of
chemotherapy: a report by the French Belgian Swiss APL group
(APL 2006 trial). Haematologica. 2018;103:e519–21.
25. Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic
trioxide-based consolidation chemotherapy spares anthracycline
exposure in the primary management of acute promyelocytic
leukemia. J Clin Oncol. 2010;28:1047–53.
26. Schemper M, Smith TL. A note on quantifying follow-up in
studies of failure time. Control Clin Trials. 1996;17:343–6.
27. Kaplan E, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457–81.
28. Gray RJ. A class of k-sample tests for comparing the cumulative
incidence of a competing risk. Ann Stat. 1988;168:1141–54.
29. Cox DR. Regression models and life tables (with discussion). J R
Stat Soc. 1972;34:187–220.
30. R Development Core Team. R: a language and environment for
statistical computing. Vienna: R Foundation for Statistical Com-
puting; 2014.
31. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute
promyelocytic leukemia: recommendations from an expert panel on
behalf of the European LeukemiaNet. Blood. 2009;113:1875–91.
32. Jillella AP, Kota VK. The global problem of early deaths in acute
promyelocytic leukemia: a strategy to decrease induction mortality
in the most curable leukemia. Blood Rev. 2018;32:89–95.
33. Martínez-Cuadrón D, Montesinos P, Vellenga E, et al. Long-term
outcome of older patients with newly diagnosed de novo acute
promyelocytic leukemia treated with ATRA plus anthracycline-
based therapy. Leukemia. 2018;32:21–9.
34. de la Serna J, Montesinos P, Vellenga E, et al. Causes and
prognostic factors of remission induction failure in patients with
acute promyelocytic leukemia treated with all-trans retinoic acid
and idarubicin. Blood. 2008;11:3395–4302.
35. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves
event-free and overall survival for adults with acute promyelocytic
leukemia: North American Leukemia Intergroup Study C9710.
Blood. 2010;116:3751–7.
36. Pagano L, Pulsoni A. Second malignancy after treatment of acute
promyelocytic leukemia: experience of GIMEMA trials. Blood.
2002;100:1514–5.
37. Schlenk RF, Germing U, Hartmann F, et al. High-dose cytarabine
and mitoxantrone in consolidation therapy for acute promyelo-
cytic leukemia. Leukemia. 2005;19:978–83.
38. Lou Y, Suo S, Tong H, et al. Characteristics and prognosis ana-
lysis of additional chromosome abnormalities in newly diagnosed
acute promyelocytic leukemia treated with arsenic trioxide as the
front-line therapy. Leuk Res. 2013;37:1451–6.
39. Grimwade D, Walker H, Harrison G, et al. The predictive value of
hierarchical cytogenetic classification in older adults with acute
myeloid leukemia (AML): analysis of 1065 patients entered into
the United Kingdom Medical Research Council AML11 trial.
Blood. 2001;98:1312–20.
40. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of
FLT3 associated with leukocytosis in acute promyelocytic leu-
kemia. Leukemia Study Group of the Ministry of Health and
Welfare (Kohseisho). Leukemia. 1997;11:1447–52.
41. Noguera NI, Breccia M, Divona M, et al. Alterations of the FLT3
gene in acute promyelocytic leukemia: association with diag-
nostic characteristics and analysis of clinical outcome in patients
treated with the Italian AIDA protocol. Leukemia. 2002;16:
2185–9.
42. Shih LY, Kuo MC, Liang DC, et al. Internal tandem duplication
and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3)
gene in acute promyelocytic leukemia. Cancer. 2003;98:
1206–16.
43. Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem
duplication of the FLT3 gene confers poor overall survival in
patients with acute promyelocytic leukemia treated with all-trans
retinoic acid and anthracycline-based chemotherapy: an Interna-
tional Consortium on Acute Promyelocytic Leukemia study. Ann
Hematol. 2014;93:2001–10.
44. De Botton S, Chevret S, Sanz M, et al. Additional chromosomal
abnormalities in patients with acute promyelocytic leukaemia
(APL) do not confer poor prognosis: results of APL 93 trial. Br J
Haematol. 2000;111:801–6.
45. Cervera J, Montesinos P, Hernández-Rivas JM, et al. Additional
chromosome abnormalities in patients with acute promyelocytic
leukemia treated with all-trans retinoic acid and chemotherapy.
Haematologica. 2010;95:424–31.
46. Pantic M, Novak A, Marisavljevic D, et al. Additional chromo-
some aberrations in acute promyelocytic leukemia: characteristics
and prognostic influence. Med Oncol. 2000;17:307–13.
47. Poiré X, Moser BK, Gallagher RE, et al. Arsenic trioxide in front-
line therapy of acute promyelocytic leukemia (C9710): prognostic
significance of FLT3 mutations and complex karyotype. Leuk
Lymphoma. 2014;55:1523–32.
48. Cicconi L, Divona M, Ciardi C, et al. PML-RARα kinetics and
impact of FLT3-ITD mutations in newly diagnosed acute pro-
myelocytic leukaemia treated with ATRA and ATO or ATRA and
chemotherapy. Leukemia. 2016;30:1987–92.
49. Sanz MA, Vellenga E, Rayón C, et al. All-trans retinoic acid and
anthracycline monochemotherapy for the treatment of elderly
patients with acute promyelocytic leukemia. Blood. 2004;104:
3490–3.
50. Lengfelder E, Hanfstein B, Haferlach C, et al. Outcome of elderly
patients with acute promyelocytic leukemia: results of the German
Acute Myeloid Leukemia Cooperative Group. Ann Hematol.
2013;92:41–52.
2340 S. Kayser et al.
Affiliations
Sabine Kayser1,2,3 ● Ramy Rahmé4 ● David Martínez-Cuadrón5,6 ● Gabriel Ghiaur7 ● Xavier Thomas8 ● Marta Sobas9 ●
Agnes Guerci-Bresler10 ● Ana Garrido11 ● Arnaud Pigneux12 ● Cristina Gil13 ● Emmanuel Raffoux14 ● Mar Tormo15 ●
Norbert Vey16 ● Javier de la Serna17 ● Olga Salamero18 ● Eva Lengfelder19 ● Mark J. Levis 7 ● Pierre Fenaux4 ●
Miguel A. Sanz5,6 ● Uwe Platzbecker1 ● Richard F. Schlenk3,20 ● Lionel Adès4 ● Pau Montesinos 5,6
1 Medical Clinic and Policlinic I, Hematology and Cellular Therapy,
University Hospital Leipzig, Leipzig, Germany
2 German Cancer Research Center (DKFZ), Heidelberg, Germany
3 Department of Internal Medicine V, Heidelberg University
Hospital, Heidelberg, Germany
4 Hôpital Saint Louis, Université Paris Diderot, Paris, France
5 Hematology Department, Hospital Universitari i Politècnic, La Fe,
Avinguda Fernando Abril Martorell, 106, 46026 València, Spain
6 CIBERONC, Instituto Carlos III, Madrid, Spain
7 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
University, Baltimore, MD, USA
8 Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud,
Pierre Bénite, Lyon, France
9 Department of Hematology, Blood Neoplasms and Bone Marrow
Transplantation, Wroclaw Medical University, Wroclaw, Poland
10 Department of Hematology, Nancy University Hospital,
Nancy, France
11 Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de
Barcelona, Barcelona, Spain
12 Department of Hematology, Bordeaux University Hospital,
Bordeaux, France
13 Hospital General, Alicante, Spain
14 Hôpital Saint Louis, Université Paris Diderot, Paris, France
15 Hematology Department, Hospital Clínico Universitario,
INCLIVA Research Institute, University of Valencia,
Valencia, Spain
16 Institut Paoli Calmette, Marseille, France
17 Hospital 12 de Octubre, Madrid, Spain
18 Hospital Universitario Vall d´Hebron, Barcelona, Spain
19 Department of Hematology and Oncology, University Hospital
Mannheim, Mannheim, Germany
20 NCT Trial Center, National Center for Tumor Diseases, German
Cancer Research Center and Heidelberg University Hospital,
Heidelberg, Germany
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an. . . 2341
